LOGIN
Alendronate is an effective way of increasing BMD and reducing bone turnover
March 2014
Alendronate is an effective way of increasing BMD and reducing bone turnover
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
The safety and efficacy of early-stage bi-weekly alendronate to improve bone mineral density and bone turnover in chinese post-menopausal women at risk of osteoporosis
J Int Med Res. 2011;39(1):302-10Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
180 post-menopausal Chinese women, between 40 and 70 years of age, with osteopenia (T-score between -1.6 and -2.4), were randomized into 1 of 2 groups to study the effects of early antiresorptive drug intervention on osteopenia. The first group, classified as the treatment group, was given received 70 mg of alendronate once every 2 weeks plus 0.5 micrograms of alfacalcidol daily, while the second ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.